BPOM Head Urges Triple Helix Synergy to Achieve National Pharmaceutical Raw Material Independence

The quest for national sovereignty in the healthcare sector has once again taken center stage as Indonesia grapples with a persistent reliance on foreign pharmaceutical ingredients. In a decisive push to reverse this vulnerability, Prof. Dr. Taruna Ikrar, Head of the Indonesian Food and Drug Authority (BPOM), has issued a robust call for heightened cooperation among academic institutions, industrial players, and government bodies. Speaking at a prominent scientific gathering in Surabaya, the BPOM chief underscored that achieving self-sufficiency in active pharmaceutical ingredients (APIs) is no longer merely an economic ambition, but a critical pillar of national security.
The appeal was formally delivered during the prestigious Science, Technology, and Industrial Convention 2026, hosted at the Institut Teknologi Sepuluh Nopember in Surabaya. Addressing an audience of policymakers, researchers, and industry leaders, Prof. Taruna presented a compelling roadmap titled National Pharmaceutical Raw Material Independence. His address cut to the heart of one of Indonesia’s most enduring structural challenges: the heavy import dependence that characterizes the domestic pharmaceutical landscape.
Chronology and Background of the Convention
The Science, Technology, and Industrial Convention 2026 served as the premier backdrop for these vital discussions. Running from November 10 to November 13, the multi-day event established itself as a critical melting pot for intellectual discourse, technological showcase, and cross-sector networking. The convention drew regional and international attention, notably through the participation of high-profile global figures, including Prof. Benjamin List, the Nobel Laureate in Chemistry for 2021. The presence of such a distinguished scholar elevated the dialogue, bridging cutting-edge global scientific breakthroughs with local implementation challenges.
On Thursday, November 12, the specific session addressing pharmaceutical sovereignty took center stage. The forum was meticulously designed to foster dialogue on how Indonesia can leverage its rich biodiversity and growing technological infrastructure to transition from an import-dependent consumer market into a self-reliant producer of essential medicines. Following the event, official releases disseminated on Friday, November 13, further amplified the core takeaways of Prof. Taruna’s address, crystallizing the urgency of structural reform within the country’s healthcare manufacturing sector.
The Anatomy of Import Dependence
To understand the gravity of Prof. Taruna’s remarks, one must examine the baseline data governing Indonesia’s pharmaceutical ecosystem. Historically, the nation imports roughly 90 percent of its active pharmaceutical ingredients—the core chemical compounds that give medicines their therapeutic properties—primarily from industrial powerhouses such as China and India. While Indonesia boasts a robust domestic formulation sector capable of packaging and distributing finished medicinal products, the upstream vulnerability remains a severe structural bottleneck.
This high degree of import reliance exposes the domestic healthcare supply chain to external macroeconomic shocks. Currency fluctuations, geopolitical tensions, global supply chain disruptions, and sudden export restrictions by producer nations can severely jeopardize the availability of essential medicines for Indonesia’s vast population. During global crises, such as the lingering disruptions inherited from pandemic-era logistical bottlenecks, the cost of procuring raw materials spikes unpredictably, placing immense fiscal pressure on the national health insurance scheme and out-of-pocket consumers alike.
The Triple Helix Framework for Reform
Addressing this systemic vulnerability requires more than incremental adjustments; it demands a complete overhaul of how research, commercialization, and regulation intersect. During his convention presentation, Prof. Taruna championed the classic yet vital "Triple Helix" framework, which interlocks academia, business, and government into a cohesive operational engine.
According to the BPOM leadership, each stakeholder holds a distinct, non-substitutable responsibility within this collaborative matrix. Academic institutions, particularly leading technological and scientific universities like the host institution ITS, must position themselves as dynamic centers of innovation. Rather than confining research to theoretical frameworks and academic journals, university laboratories must direct their intellectual capital toward solving practical industrial problems, such as synthesizing complex chemical compounds and extracting therapeutic agents from Indonesia’s rich indigenous flora.
Simultaneously, the private industrial sector must step forward as the primary driver of capital investment and commercialization. Research breakthroughs hold little societal value if they remain trapped within university walls. Industries must possess the risk appetite and financial foresight to scale up laboratory-scale discoveries into mass-production facilities capable of meeting commercial demand standards. This involves investing in state-of-the-art bioreactors, chemical synthesis plants, and stringent quality control infrastructure.
Finally, the government—through regulatory bodies like BPOM alongside ministries of industry, health, and education—must act as the foundational enabler. This involves streamlining regulatory pathways, offering targeted fiscal incentives, protecting intellectual property rights, and establishing clear compliance standards that guarantee product safety and efficacy without stifling innovation.
Bridging the Gap Between Publication and Product
A central theme of the BPOM Head’s critique was the historical disconnect within Indonesia’s research ecosystem, where brilliant scientific discoveries frequently languish in academic archives without ever transitioning into commercial utility. Prof. Taruna stressed that synergy among the three pillars is the absolute key to transforming scholarly output into marketable commodities that generate tangible economic value and broad public benefit.
When universities collaborate directly with pharmaceutical companies from the early stages of molecule discovery, the resulting innovations are inherently tailored to market needs and regulatory standards. Furthermore, regulatory agencies must engage early in the development cycle, providing scientific advice and pre-submission guidance to researchers and industrialists. This proactive regulatory approach prevents costly delays down the line, ensuring that homegrown products can navigate the rigorous authorization processes required for public distribution.
Implications and Broader Economic Impact
The implications of successfully achieving national pharmaceutical raw material independence extend far beyond public health security; they represent a massive economic opportunity for Indonesia. By fostering a domestic API manufacturing sector, the country can retain billions of rupiah previously lost to foreign exchange outflows, redirecting that capital toward domestic job creation, advanced technical training, and further research and development initiatives.
Moreover, a localized supply chain enhances the resilience of the National Health Insurance system. Predictable, locally sourced raw material costs protect the healthcare budget from the volatile swings of international currency markets, ensuring long-term fiscal sustainability. It also positions Indonesia as a potential regional exporter of pharmaceutical ingredients, leveraging the nation’s strategic geographic position within Southeast Asia and its burgeoning bilateral trade partnerships.
Path Forward and Future Outlook
As the Science, Technology, and Industrial Convention 2026 concluded, the momentum generated by high-level discussions must now translate into concrete policy execution. The roadmap articulated by BPOM provides a clear conceptual blueprint, but its success relies entirely on sustained, cross-sectoral follow-through.
The integration of global expertise—exemplified by international luminaries like Prof. Benjamin List—alongside the institutional commitment of domestic powerhouses such as ITS and BPOM, signals a promising trajectory. If Indonesia successfully synchronizes the innovative capacity of its academics, the financial muscle of its industrialists, and the regulatory stewardship of its government, the vision of a self-reliant pharmaceutical sector will transition from an ambitious policy goal into an undeniable reality, securing a healthier and more resilient future for the entire nation.







